Anzeige
Mehr »
Login
Sonntag, 22.12.2024 Börsentäglich über 12.000 News von 679 internationalen Medien
Die erste börsennotierte Gesellschaft, die auf das gemeinsame Wachstum von Solana, XRP und Dogecoin setzt!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3C4HE | ISIN: US29415J1060 | Ticker-Symbol: 5HJ
Tradegate
20.12.24
15:33 Uhr
2,540 Euro
+0,120
+4,96 %
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
ENVVENO MEDICAL CORPORATION Chart 1 Jahr
5-Tage-Chart
ENVVENO MEDICAL CORPORATION 5-Tage-Chart
RealtimeGeldBriefZeit
2,3802,44020.12.

Aktuelle News zur ENVVENO MEDICAL Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
FrNVNO stock touches 52-week low at $2.5 amid market challenges1
ENVVENO MEDICAL Aktie jetzt für 0€ handeln
FrNVNO-Aktie erreicht 52-Wochen-Tief bei 2,5 US-Dollar1
MoenVVeno Medical Corporation: enVVeno Medical Successfully Completes Final Wave of Implants in Pre-Clinical GLP Study for enVVe110Successful Completion of All Planned Implants in GLP StudyenVVe Delivery System Demonstrates Consistent PerformanceCompany Maintains Timeline for IDE Application Submission by Mid-2025, Pending GLP...
► Artikel lesen
12.12.NVNO Stock Touches 52-Week Low at $2.9 Amid Market Challenges1
12.12.NVNO-Aktie erreicht 52-Wochen-Tief bei 2,9 US-Dollar1
03.12.NVNO Stock Touches 52-Week Low at $3.01 Amid Market Challenges1
03.12.NVNO-Aktie erreicht 52-Wochen-Tief bei 3,01 US-Dollar1
27.11.enVVeno Medical Corporation: enVVeno Medical Highlights Successful 2024 VEITH Symposium with Launch of Recap Website178Interviews with participating patients from the VenoValve® U.S. Pivotal TrialWebcast replay from with the presenting Primary InvestigatorsPresentation with data from the VenoValve U.S. Pivotal TrialAccess...
► Artikel lesen
25.11.NVNO Completes Application for VenoValve's PMA, Shares Likely to Gain2
20.11.enVVeno Medical Corporation: enVVeno Medical to Present Definitive One Year Data from the VenoValve U.S. Pivotal Trial Today at the 51st Annual VEITH Symposium17785% Clinical Meaningful Benefit Responder Rate7.91 Point Average rVCSS Improvement for the Clinically Meaningful Benefit Responder Cohort75% Median Reduction in Pain (VAS)87% Median Ulcer Area Reduction97%...
► Artikel lesen
19.11.enVVeno Medical strebt FDA-Zulassung für VenoValve an3
19.11.enVVeno Medical Corporation: enVVeno Medical Submits the VenoValve PMA Application Seeking FDA Approval422Definitive One Year Data from PMA Application to be Presented Wednesday at 51st Annual VEITH SymposiumCompany to Host a Conference Call with the PIs Presenting the Pivotal Trial Data on Wednesday, November...
► Artikel lesen
19.11.enVVeno Medical seeks FDA approval for VenoValve2
31.10.enVVeno Medical Corporation: enVVeno Medical Reports Third Quarter 2024 Financial Results and Confirms Guidance for Release of Definitive VenoValve Data in November and Completion of FDA Premarket Approval Application for VenoValve in Q4 of this Year146Continued progress toward submission of 5th and final module of FDA premarket approval (PMA) application for VenoValve® in Q4GLP study for enVVe® transcatheter-based replacement venous valve underway...
► Artikel lesen
28.10.enVVeno Medical Corporation: enVVeno Medical Successfully Initiates 6-Month Pre-Clinical GLP Study Evaluating enVVe198First wave of implants successfully completed with updated delivery system performing very wellCompany on schedule to be in position to apply for approval for enVVe pivotal trial mid-2025 IRVINE, CA...
► Artikel lesen
08.10.NVNO Stock Hits 52-Week Low at $3.06 Amid Market Challenges2
08.10.NVNO-Aktie erreicht 52-Wochen-Tief bei 3,06 US-Dollar1
30.09.enVVeno Medical Corp - 8-K, Current Report2
27.09.NVNO-Aktie erreicht 52-Wochen-Tief bei 3,4 US-Dollar1
27.09.NVNO stock touches 52-week low at $3.4 amid market challenges1
Seite:  Weiter >>
44 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1